信州大学HOMEENGLISH交通・キャンパス案内

研究者総覧研究者総覧

研究者、研究内容などで検索
項目別検索はこちら

青村 大輝  アオムラ ダイキ

教員組織電話番号
教育組織医学部 医学科 健康推進学(寄附講座)FAX番号
職名助教(特定雇用)メールアドレス
住所〒390-8621 長野県松本市旭3-1-1ホームページURL

プロフィール

研究分野
病態医化学
腎臓内科学
所属学会
所属学会
日本透析医学会
日本腎臓学会
日本内科学会
学歴
出身大学院
信州大学 , 大学院 医学系研究科

出身学校・専攻等(大学院を除く)
2015 , 信州大学 , 医学部 , 医学科

取得学位
医学博士 , 信州大学
医学学士 , 信州大学
受賞学術賞
2022 , 研究奨励賞(信州大学医学部医学科)
2022 , 同門会賞(信州大学第二内科同門会)
2022 , 竹内松次郎賞(信州大学医学部)
2019 , 氷川賞(第15回氷川フォーラム)
2016 , ベストプレゼンテーション賞(第118回信州整形外科懇談会)
研究職歴等
研究職歴
2018- , 信州大学医学部附属病院 腎臓内科
2017-2018 , 諏訪赤十字病院 腎臓内科
2015-2017 , 信州大学 医学部附属病院 卒後臨床研修センター

研究活動業績

研究業績(著書・
発表論文等)
論文
Early detection of thiamine deficiency by non-thyroidal illness syndrome in a hemodialysis patient.
CEN case reports 2022(Aug. 26)
Author:Daiki Aomura; Yukifumi Kurasawa; Makoto Harada; Koji Hashimoto; Yuji Kamijo
Abstract:An 88-year-old male patient on maintenance hemodialysis (HD) therapy experienced gradual losses in appetite and liveliness during the course of 1 month. Physical examinations revealed no abnormalities. However, blood testing indicated non-thyroidal illness syndrome (NTIS) typically observed in patients with severe illness, with serum levels of thyroid stimulating hormone, free triiodothyronine, and free thyroxine of 0.17 μIU/mL, < 1.0 pg/mL, and 0.23 ng/dL, respectively. Brain magnetic resonance imaging to exclude the possibility of central hypothyroidism unexpectedly displayed slight abnormalities inside of the thalami that were characteristic of Wernicke's encephalopathy. Additional examination disclosed low serum thiamine of 20 ng/mL. Thiamine injections of 100 mg at every HD treatment rapidly restored his appetite, liveliness, and NTIS findings. HD patients are at a particularly high risk of thiamine deficiency (TD) and associated severe symptoms due to losses of thiamine during HD sessions. However, its non-specific initial symptoms, including decreases in appetite and liveliness, as well as undetectability in routine blood tests complicate early detection, resulting in underdiagnosis and more severe outcomes. In the present case, TD manifested only as non-specific symptoms and was ultimately revealed by the presence of NTIS, which was resolved with thiamine supplementation. Thus, NTIS might assist in the early detection of TD as an initial sign in HD patients.


Brain MRI detection of early Wernicke’s encephalopathy in a hemodialysis patient
Clinical Case Reports,10(3) 2022(Mar.)
Author:Daiki Aomura; Yukifumi Kurasawa; Makoto Harada; Koji Hashimoto; Yuji Kamijo


Relationship between glomerular number in fresh kidney biopsy samples and light microscopy samples
Clinical and Experimental Nephrology 2022(Feb. 01)
Author:Kosuke Sonoda; Makoto Harada; Daiki Aomura; Yuuta Hara; Yosuke Yamada; Akinori Yamaguchi; Koji Hashimoto; Yuji Kamijo


Serum Sulfatide Levels as a Biomarker of Active Glomerular Lesion in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Pilot Study.
Journal of clinical medicine,11(3) 2022(Jan. 30)
Author:Makoto Harada; Takero Nakajima; Yosuke Yamada; Daiki Aomura; Akinori Yamaguchi; Kosuke Sonoda; Naoki Tanaka; Koji Hashimoto; Yuji Kamijo
Abstract:Sulfatides are glycosphingolipids that are associated with coagulation and platelet aggregation. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) activates platelet function and often leads to thrombotic complications. These facts suggest an association between serum sulfatides and AAV. We aimed to clarify the significance of serum sulfatide levels in patients with AAV. We conducted a retrospective, single-center, observational pilot study that included 35 patients who developed AAV and 10 control patients who were candidates for living-donor kidney transplantation. We compared serum sulfatide levels between the control and AAV patients. We analyzed the differences in serum sulfatide levels among four classes (focal, crescentic, mixed, and sclerotic class) of glomerular lesions that were categorized by histopathologic classification of ANCA-associated glomerulonephritis. Serum sulfatide levels in patients with AAV were significantly lower than those in the controls. Serum sulfatide levels were significantly different between the four classes. Additionally, serum sulfatide levels in the crescentic class were significantly lower than those in the other classes. Serum sulfatide levels were significantly correlated with albumin, cholesterol, C-reactive protein, and pentraxin 3. In conclusion, serum sulfatide levels are significantly correlated with inflammation, reflecting crescentic glomerulonephritis, which is an active glomerular lesion in AAV patients.


Hospital Admission to a Window-Side Bed Does Not Prevent Delirium: A Retrospective Cohort Study of Older Medical Inpatients in General Wards
Frontiers in Medicine,8 2021(Sep. 14)
Author:Daiki Aomura; Yosuke Yamada; Makoto Harada; Koji Hashimoto; Yuji Kamijo
Abstract:Background: Delirium in older inpatients is a serious problem. The presence of a window in the intensive care unit has been reported to improve delirium. However, no study has investigated whether window-side bed placement is also effective for delirium prevention in a general ward.Objectives: This study aims to clarify the association between admission to a window-side bed and delirium development in older patients in a general ward.Design: This research is designed as a retrospective cohort study of older patients admitted to the internal medicine departments of Shinshu University Hospital, Japan.Participants: The inclusion criteria were the following: (1) admitted to hospital internal medicine departments between April 2009 and December 2018, (2) older than 75 years, (3) admitted to a multi-patient room in a general ward, and (4) unplanned admission. The number of eligible patients was 1,556.Exposure: This study is a comparison of 495 patients assigned to a window-side bed (window group) with 1,061 patients assigned to a non-window-side bed (non-window group). When patients were transferred to the other type bed after admission, observation was censored.Main Measures: The main outcome of interest was “delirium with event” (e.g., the use of medication or physical restraint for delirium) within 14 days after admission as surveyed by medical chart review in a blinded manner.Key Results: The patients had a median age of 80 years and 38.1% were female. The main outcome was recorded in 36 patients in the window group (10.7 per thousand person-days) and 84 in the non-window group (11.7 per thousand person-days). Log-rank testing showed no significant difference between the groups (p = 0.78). Multivariate analysis with Cox regression modeling also revealed no significant association for the window group with main outcome development (adjusted hazard ratio 0.90, 95% confidence interval of 0.61–1.34).Conclusions: Admission to a window-side bed did not prevent delirium development in older patients admitted to a general ward.


Comparison of the factors associated with the short-term prognosis between elderly and non-elderly patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective observational study.
Clinical and experimental rheumatology 2021(Sep. 09)
Author:Makoto Harada; Akinori Yamaguchi; Kosuke Sonoda; Yosuke Yamada; Daiki Aomura; Yutaka Kamimura; Koji Hashimoto; Tohru Ichikawa; Mamoru Kobayashi; Yuji Kamijo
Abstract:OBJECTIVES: The difference in factors associated with the prognosis between elderly and non-elderly patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is uncertain. We aimed to elucidate the clinical factors associated with the short-term prognosis (within 6 months from the start of the treatment) and investigate the differences in the associated factors between elderly and non-elderly individuals. METHODS: We performed a dual centre retrospective observational study of patients newly treated with AAV (eosinophilic granulomatous with polyangiitis was excluded). The primary outcome was all-cause death, and the secondary outcome was end-stage renal disease (ESRD) and infectious complications within 6 months after the start of treatment. We analysed factors associated with these outcomes using logistic regression analyses. RESULTS: Of the 79 patients, patients aged ≥75 years were defined as elderly (n=41), whereas those aged <75 years were de¬fined as non-elderly (n=38). In elderly patients, age was significantly associated with all-cause mortality. In the non-elderly patients, the geriatric nutritional risk index was significantly associated with all-cause death. The estimated glomerular filtration rate (eGFR) before the start of treatment was significantly associated with ESRD in elderly and non-elderly patients. In elderly patients, the Birmingham vasculitis score 3, eGFR, methylprednisolone pulse use, and cyclophosphamide use were significantly associated with infectious complications. Factors other than the serum albumin level were not significantly associated with infectious complications in the non-elderly population. CONCLUSIONS: The factors associated with all-cause death and infectious complications differed between elderly and non-elderly patients. Awareness of these differences may contribute to better management of AAV.


Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project
PLOS ONE,16(8):e0256711-e0256711 2021(Aug. 26)
Author:Hiroyuki Kobayashi; Satoru Joshita; Yuki Akahane; Katsuhiko Matsuzaki; Hiromi Yamada; Daiki Aomura; Nao Joshita; Hajime Midorikawa; Kazuhiro Suyama; Masao Ota; Shun-ichi Wakabayashi; Yuki Yamashita; Ayumi Sugiura; Tomoo Yamazaki; Hiromichi Misawa; Takeji Umemura
Abstract: Background The World Health Organization has set a goal of hepatitis C virus (HCV) elimination by the year 2030. However, no regions in Japan have succeeded in eradicating HCV. Micro-elimination is an approach to attain hepatitis C eradication in which national eradication goals are applied to specific populations so that viral treatment and control efforts can move forward quickly and efficiently. In order to eradicate HCV from Japan, this study aims to achieve HCV micro-elimination in the town of Nagawa. Methods and design The Nagawa Project is an ongoing, prospective, multiple-institution, observational study running from April 1, 2021, to March 31, 2024. All residents of Nagawa town, excluding those under 20 years of age, not consenting to the study, or unable to undergo health check-ups due to nursing care needs, will be included. If found to be HCV antibody-positive, the participant will be recommended to see a doctor in consideration of MAC-2 binding protein glycosylation isomer values. Then, the participant will undergo serum HCV RNA measurement with the real-time polymerase chain reaction by an attending physician. If the participant is HCV RNA-positive, he or she will be referred to a hepatologist for further evaluation. In the case of a definitive diagnosis of chronic hepatitis C, direct acting antiviral treatment will be initiated. Through this process, HCV will be systematically micro-eliminated from the region. Discussion The Nagawa Project will reveal the prevalence of chronic HCV in addition to the HCV eradication rate in Nagawa town towards achieving HCV micro-elimination. Trial registration This study is performed by Shinshu University School of Medicine and was registered as UMIN 000044114 on May 6, 2021.


Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism.
Metabolites,11(6) 2021(Jun. 09)
Author:Daiki Aomura; Makoto Harada; Yosuke Yamada; Takero Nakajima; Koji Hashimoto; Naoki Tanaka; Yuji Kamijo
Abstract:As classical agonists for peroxisomal proliferator-activated receptor alpha (PPARα), fibrates activate renal fatty acid metabolism (FAM) and provide renoprotection. However, fibrate prescription is limited in patients with kidney disease, since impaired urinary excretion of the drug causes serious adverse effects. Pemafibrate (PEM), a novel selective PPARα modulator, is mainly excreted in bile, and, thus, may be safe and effective in kidney disease patients. It remains unclear, however, whether PEM actually exhibits renoprotective properties. We investigated this issue using mice with fatty acid overload nephropathy (FAON). PEM (0.5 mg/kg body weight/day) or a vehicle was administered for 20 days to 13-week-old wild-type male mice, which were simultaneously injected with free fatty acid (FFA)-binding bovine serum albumin from day 7 to day 20 to induce FAON. All mice were sacrificed on day 20 for assessment of the renoprotective effect of PEM against FAON. PEM significantly attenuated the histological findings of tubular injury caused by FAON, increased the renal expressions of mRNA and proteins related to FAM, and decreased renal FFA content and oxidative stress. Taken together, PEM exhibits renoprotective effects through the activation and maintenance of renal FAM and represents a promising drug for kidney disease.


Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B.
Case reports in nephrology and dialysis 2020(Oct. 15)
Author:Daiki Aomura; Naoki Tachibana; Michiharu Komatsu; Masakazu Kobayashi
Abstract:A male hepatitis B virus (HBV) carrier in his 40s under hemodialysis treatment exhibited chronic hepatitis (alanine aminotransferase: 41 IU/L, HBV-DNA: >9.1 log copies/mL). Following discontinuation of the initial treatment with pegylated interferon-α-2a at 24 weeks due to adverse effects, the administration of tenofovir disoproxil fumarate (TDF) (300 mg/week) led to a rapid improvement in hepatitis markers: HBV DNA became undetectable at month 34, and seroconversion of hepatitis B envelope antigen was confirmed at 45 months. No side effects were recorded during TDF treatment. TDF is a newly approved nucleoside analogue that may cause severe side effects via proximal tubular injury in patients with renal dysfunction. However, few reports have described its use in hemodialysis patients, whose anuric state may render them less susceptible to side effects including kidney injury. Hepatitis improved remarkably without any adverse drug reactions in the present case. TDF may therefore be considered for chronic hepatitis B patients receiving hemodialysis.


A Case of Acute Kidney Injury in a Patient with Renal Hypouricemia without Intense Exercise.
Case reports in nephrology and dialysis 2020(Mar. 30)
Author:Daiki Aomura; Kosuke Sonoda; Makoto Harada; Koji Hashimoto; Yuji Kamijo
Abstract:Exercise-induced acute kidney injury (EIAKI) frequently develops in patients with renal hypouricemia (RHUC). However, several cases of RHUC with acute kidney injury (AKI) but without intense exercise have been reported. We encountered a 15-year-old male with RHUC who experienced AKI. He reported no episodes of intense exercise and displayed no other representative risk factors of EIAKI, although a vasopressor had been administered for orthostatic dysregulation before AKI onset. His kidney dysfunction improved with discontinuation of the vasopressor and conservative treatment. Thus, AKI can develop in patients with RHUC in the absence of intense exercise, for which vasopressors may be a risk factor.


Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism.
Internal medicine (Tokyo, Japan) 2019(Nov. 08)
Author:Daiki Aomura
Abstract:A 47-year-old man was admitted to our hospital because of thrombocytopenia and consciousness disturbance. As his laboratory data showed undetectable activity of a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) and the presence of ADAMTS13 inhibitor, he was diagnosed with acquired thrombotic thrombocytopenic purpura (TTP). Asymptomatic primary Sjögren's syndrome (SS) and primary hypothyroidism were incidentally diagnosed on screening. After initial plasma exchange therapy and pulse corticosteroid therapy, the patient received rituximab therapy for refractory TTP with "inhibitor boosting" and recovered. TTP secondary to primary SS is rare but can trigger refractory TTP. Treatment with rituximab, which is considered "inhibitor boosting," should be considered when re-exacerbation occurs.


講演・口頭発表等
近位尿細管のPPARαは全身の飢餓応答に関与する
第64回日本腎臓学会学術総会 2021(Jun. 18)
Presenter:青村大輝; 山田洋輔; 上條祐司


近位尿細管特異的PPARα conditional K.O.マウスの確立と飢餓応答について
第18回氷川フォーラム 2020(Nov. 14)
Presenter:青村大輝; 山田洋輔; 上條祐司


内科入院患者における窓際病床への入院とせん妄発症率の関連性の検討
第117回日本内科学会総会 2020
Presenter:青村大輝; 山田洋輔; 上條祐司


Pemafibrate exerts renoprotective effects by activation of PPARα in murine kidneys
ASN Kidney Week 2019 2019(Nov. 07)
Presenter:Aomura D; Nishikawara M; Kamijo Y


ペマフィブラートはPPARα活性化を介した脂質代謝改善および尿蛋白減少効果を発揮する
第62回日本腎臓学会学術総会 2019(Jun. 23)
Presenter:青村大輝; 山田洋輔; 上條祐司


選択的PPARα修飾薬(SPPARMα)による腎保護効果の検討
第15回氷川フォーラム 2019(May 18)
Presenter:青村大輝; 山田洋輔; 上條祐司


Influence of Arteriovenous Fistula on Daily Living Behaviors Involving the Upper Limbs in Hemodialysis Patients: A Questionnaire Study
ASN Kidney Week 2018 2018(Oct. 27)
Presenter:Aomura D; Kurihara S; Nimura M; Kamijo Y


エチレフリン塩酸塩の内服中に、日常レベルの動作で運動後急性腎障害を発症した腎性低尿酸血症の一例
第48回日本腎臓学会東部学術大会 2018(Oct. 21)
Presenter:青村大輝; 園田光佑; 上條祐司


糖尿病性腎症にMPO-ANCA陽性の多発血管性肉芽腫症(GPA)を合併した一例
第47回日本腎臓学会東部学術大会 2017(Oct. 28)
Presenter:青村大輝; 立花直樹; 笠原寛


第 1 腰椎破裂骨折に合併した馬尾ヘルニアの 1 例
第118回信州整形外科懇談会 2016(Aug. 20)
Presenter:青村大揮; 清水政幸; 髙橋 淳


MISC
内科一般病床に入院した高齢患者における,「窓際病床への入院」と「せん妄発症」の関連性の検討:単施設における後方視的コホート研究
長野県医学会雑誌,51 2021
Author:青村大輝; 山田洋輔; 原田真; 橋本幸始; 上條祐司


内科入院患者における窓際病床への入院とせん妄発症率の関連性の検討
日本内科学会雑誌,109(Suppl.):245 2020(Feb.)
Author:青村 大輝; 山田 洋輔; 島崎 雅士; 原田 真; 橋本 幸始; 上條 祐司


選択的PPARα修飾薬(SPPARMα)による腎保護効果の検討
腎と脂質研究会プログラム・抄録集,32nd 2020
Author:青村大輝; 山田洋輔; 岩渕良平; 原田真; 中嶌岳郎; 橋本幸始; 上條祐司


ペマフィブラートはPPARα活性化を介した脂質代謝改善および尿蛋白減少効果を発揮する
日本腎臓学会誌,61(3):413 2019(May)
Author:青村 大輝; 山田 洋輔; 中嶌 岳郎; 橋本 幸始; 上條 祐司


エチレフリン塩酸塩の内服中に,日常レベルの動作で運動後急性腎障害を発症した腎性低尿酸血症の一例
日本腎臓学会誌,60(6):881 2018(Aug.)
Author:青村 大輝; 園田 光佑; 山口 晃典; 倉澤 幸史; 原 悠太; 藤井 一聡; 藤田 識志; 山田 洋輔; 増田 知恵; 山田 愛子; 小川 洋平; 橋本 幸始; 下条 久志; 上條 祐司


B型慢性肝炎に対してtenofovirが有用であった血液透析患者の一例
日本透析医学会雑誌,51(Suppl.1):606 2018(May)
Author:青村 大輝; 立花 直樹; 岩渕 良平; 塩澤 良一; 笠原 寛; 小松 通治; 小林 正和


糖尿病性腎症にMPO-ANCA陽性の多発血管性肉芽腫症(GPA)を合併した一例
日本腎臓学会誌,59(6):901 2017(Sep.)
Author:青村 大輝; 江原 孝史


第1腰椎破裂骨折に合併した馬尾ヘルニアの1例
信州医学雑誌,65(1):67 2017(Feb.)
Author:青村 大輝; 清水 政幸; 高橋 淳; 倉石 修吾; 池上 章太; 二木 俊匡; 上原 将志; 大場 悠己; 小関 道彦; 加藤 博之